Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Myostatin inhibits rhabdomyosarcoma cell proliferation through an Rb-independent pathway

Oncogene volume 23, pages 524–534 (2004)Cite this article

Abstract

Rhabdomyosarcoma (RMS) tumors are the most common soft-tissue sarcomas in childhood. In this investigation, we show that myostatin, a skeletal muscle-specific inhibitor of growth and differentiation is expressed and translated in the cultured RMS cell line, RD. The addition of exogenous recombinant myostatin inhibits the proliferation of RD cells cultured in growth media, consistent with the role of myostatin in normal myoblast proliferation inhibition. However, unlike normal myoblasts, upregulation of p21 was not observed. Rather, myostatin signalling resulted in the specific downregulation of both Cdk2 and its cognate partner, cyclin-E. The analysis of Rb reveals that there was no change in its phosphorylation status with myostatin treatment, consistent with D-type-cyclin–Cdk4/6 complexes being active in the absence of p21. Moreover, the activity of Rb appeared to be unchanged between treated and nontreated RD cells, as determined by the ability of Rb to bind E2F1. The examination of NPAT, a substrate of cyclin-E–Cdk2 involved in the transcriptional activation of replication-dependent histone gene expression, revealed that it undergoes a loss of phosphorylation with myostatin treatment. Supporting this, a downregulation in H4-histone gene expression was observed. These results suggest that myostatin could potentially be used as an inhibitor of RMS proliferation and define a previously uncharacterized, Rb-independent mechanism for the inhibition of muscle precursor cell proliferation by myostatin.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  • Aguanno S, Bouche M, Adamo S and Molinaro M . (1990). Cancer Res., 50, 3377–3382.

  • Albig W and Doenecke D . (1997). Hum. Genet., 101, 284–294.

  • Arthur PF . (1995). Aust. J. Agric. Res., 46, 1493–1515.

  • Bennicelli JL, Fredericks WJ, Wilson RB, Rauscher III FJ and Barr FG . (1995). Oncogene, 11, 119–130.

  • Bouche M, Canipari R, Melchionna R, Willems D, Senni MI and Molinaro M . (2000). FASEB J., 14, 1147–1158.

  • Bouche M, Senni MI, Grossi AM, Zappelli F, Polimeni M, Arnold HH, Cossu G and Molinaro M . (1993). Exp. Cell. Res., 208, 209–217.

  • Braun T, Buschhausen-Denker G, Bober E, Tannich E and Arnold HH . (1989). EMBO J., 8, 701–709.

  • Choi J, Costa ML, Mermelstein CS, Chagas C, Holtzer S and Holtzer H . (1990). Proc. Natl. Acad. Sci. USA, 87, 7988–7992.

  • Dagher R and Helman L . (1999). Oncologist, 4, 34–44.

  • Davis RJ, D'Cruz CM, Lovell MA, Biegel JA and Barr FG . (1994). Cancer Res., 54, 2869–2872.

  • Edmondson DG and Olson EN . (1989). Genes Dev., 3, 628–640.

  • Ewen ME . (2000). Genes Dev., 14, 2265–2270.

  • Feinberg AP . (1999). Cancer Res., 59, 1743s–1746s.

  • Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher III FJ, Emanuel BS, Rovera G and Barr FG . (1993). Nat. Genet., 5, 230–235.

  • Geng Y and Weinberg RA . (1993). Proc. Natl. Acad. Sci. USA, 90, 10315–10319.

  • Grobet L, Poncelet D, Royo LJ, Brouwers B, Pirottin D, Michaux C, Menissier F, Zanotti M, Dunner S and Georges M . (1998). Mamm. Genome, 9, 210–213.

  • Heintz N . (1991). Biochim. Biophys. Acta, 1088, 327–339.

  • Hofmann F and Livingston DM . (1996). Genes Dev., 10, 851–861.

  • Houghton JA, Houghton PJ, Brodeur GM and Green AA . (1981). Int. J. Cancer, 28, 409–415.

  • Hu X and Zuckerman KS . (2001). J. Hematother. Stem Cell Res., 10, 67–74.

  • Ji S, Losinski RL, Cornelius SG, Frank GR, Willis GM, Gerrard DE, Depreux FF and Spurlock ME . (1998). Am. J. Physiol., 275, R1265–R1273.

  • Kambadur R, Sharma M, Smith TP and Bass JJ . (1997). Genome Res., 7, 910–916.

  • Langley B, Thomas M, Bishop A, Sharma M, Gilmour S and Kambadur R . (2002). J. Biol. Chem., 277, 49831–49840.

  • Lee SJ and McPherron AC . (2001). Proc. Natl. Acad. Sci. USA, 98, 9306–9311.

  • Ludolph DC and Konieczny SF . (1995). FASEB J., 9, 1595–1604.

  • Ma T, Van Tine BA, Wei Y, Garrett MD, Nelson D, Adams PD, Wang J, Qin J, Chow LT and Harper JW . (2000). Genes Dev., 14, 2298–2313.

  • McPherron AC, Lawler AM and Lee SJ . (1997). Nature, 387, 83–90.

  • McPherron AC and Lee SJ . (1997). Proc. Natl. Acad. Sci. USA, 94, 12457–12461.

  • Megeney LA and Rudnicki MA . (1995). Biochem. Cell Biol., 73, 723–732.

  • Merlino G and Helman LJ . (1999). Oncogene, 18, 5340–5348.

  • Miner JH and Wold B . (1990). Proc. Natl. Acad. Sci. USA, 87, 1089–1093.

  • Niggli FK, Powell JE, Parkes SE, Ward K, Raafat F, Mann JR and Stevens MC . (1994). Br. J. Cancer, 69, 1106–1110.

  • Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM and Pagano M . (1995). Mol. Cell. Biol., 15, 2612–2624.

  • Oliver MH, Harrison NK, Bishop JE, Cole PJ and Laurent GJ . (1989). J. Cell Sci., 92, 513–518.

  • Olson EN and Klein WH . (1994). Genes Dev., 8, 1–8.

  • Osley MA . (1991). Annu. Rev. Biochem., 60, 827–861.

  • Otten AD, Firpo EJ, Gerber AN, Brody LL, Roberts JM and Tapscott SJ . (1997). Cell. Growth Differ., 8, 1151–1160.

  • Owa T, Yoshino H, Yoshimatsu K and Nagasu T . (2001). Curr. Med. Chem., 8, 1487–1503.

  • Pandita A, Zielenska M, Thorner P, Bayani J, Godbout R, Greenberg M and Squire JA . (1999). Neoplasia, 1, 262–275.

  • Pappo AS, Crist WM, Kuttesch J, Rowe S, Ashmun RA, Maurer HM, Newton WA, Asmar L, Luo X and Shapiro DN . (1993). J. Clin. Oncol., 11, 1901–1905.

  • Perry RL and Rudnick MA . (2000). Front. Biosci., 5, D750–D767.

  • Puri PL, Wu Z, Zhang P, Wood LD, Bhakta KS, Han J, Feramisco JR, Karin M and Wang JY . (2000). Genes Dev., 14, 574–584.

  • Scheidler S, Fredericks WJ, Rauscher III FJ, Barr FG and Vogt PK . (1996). Proc. Natl. Acad. Sci. USA, 93, 9805–9809.

  • Scrable H, Cavenee W, Ghavimi F, Lovell M, Morgan K and Sapienza C . (1989). Proc. Natl. Acad. Sci. USA, 86, 7480–7484.

  • Shapiro DN, Parham DM, Douglass EC, Ashmun R, Webber BL, Newton Jr WA, Hancock ML, Maurer HM and Look AT . (1991). J. Clin. Oncol., 9, 159–166.

  • Shapiro DN, Sublett JE, Li B, Downing JR and Naeve CW . (1993). Cancer Res., 53, 5108–5112.

  • Sharma M, Kambadur R, Matthews KG, Somers WG, Devlin GP, Conaglen JV, Fowke PJ and Bass JJ . (1999). J. Cell Physiol., 180, 1–9.

  • Sherr CJ and Roberts JM . (1995). Genes Dev., 9, 1149–1163.

  • Stein GS, Stein JL, van Wijnen AJ and Lian JB . (1992). Curr. Opin. Cell. Biol., 4, 166–173.

  • Szabo G, Dallmann G, Muller G, Patthy L, Soller M and Varga L . (1998). Mamm. Genome, 9, 671–672.

  • Tapscott SJ, Thayer MJ and Weintraub H . (1993). Science, 259, 1450–1453.

  • Tapscott SJ and Weintraub H . (1991). J. Clin. Invest., 87, 1133–1138.

  • Thies RS, Chen T, Davies MV, Tomkinson KN, Pearson AA, Shakey QA and Wolfman NM . (2001). Growth Factors, 18, 251–259.

  • Thomas M, Langley B, Berry C, Sharma M, Kirk S, Bass J and Kambadur R . (2000). J. Biol. Chem., 275, 40235–40243.

  • Turc-Carel C, Lizard-Nacol S, Justrabo E, Favrot M, Philip T and Tabone E . (1986). Cancer Genet. Cytogenet., 19, 361–362.

  • van den Heuvel S and Harlow E . (1993). Science, 262, 2050–2054.

  • Weintraub H, Tapscott SJ, Davis RL, Thayer MJ, Adam MA, Lassar AB and Miller AD . (1989). Proc. Natl. Acad. Sci. USA, 86, 5434–5438.

  • Yang J, Ratovitski T, Brady JP, Solomon MB, Wells KD and Wall RJ . (2001). Mol. Reprod. Dev., 60, 351–361.

  • Zhao J, Dynlacht B, Imai T, Hori T and Harlow E . (1998). Genes Dev., 12, 456–461.

  • Zhao J, Kennedy BK, Lawrence BD, Barbie DA, Matera AG, Fletcher JA and Harlow E . (2000). Genes Dev., 14, 2283–2297.

  • Zhu X, Hadhazy M, Wehling M, Tidball JG and McNally EM . (2000). FEBS Lett., 474, 71–75.

Download references

Author information

Authors and Affiliations

  1. Animal Genomics, AgResearch, Private Bag 3123, East Street, Hamilton, New Zealand

    Brett Langley, Mark Thomas, Craig McFarlane, Mridula Sharma & Ravi Kambadur

  2. Faculty of Medicine and Health Science, University of Auckland, Private Bag, Auckland, 92019, New Zealand

    Brett Langley & Stewart Gilmour

Authors
  1. Brett Langley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Craig McFarlane
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stewart Gilmour
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mridula Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ravi Kambadur
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ravi Kambadur.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Langley, B., Thomas, M., McFarlane, C. et al. Myostatin inhibits rhabdomyosarcoma cell proliferation through an Rb-independent pathway. Oncogene 23, 524–534 (2004). https://doi.org/10.1038/sj.onc.1207144

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207144

Keywords

This article is cited by

Search

Advanced search

Quick links